Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005579
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 26, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

May 2, 2000
January 27, 2003
June 26, 2013
June 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00005579 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.


  • Estimate the efficacy of dolastatin 10 in patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.
  • Evaluate the qualitative and quantitative toxicities of dolastatin 10 in this patient population.
  • Investigate the mechanism of action of dolastatin 10 in regards to apoptosis and effects of microtubules.

OUTLINE: This is an open-label, multicenter study. Patients are stratified by disease (chronic lymphocytic leukemia vs indolent lymphoma vs Waldenstrom's macroglobulinemia).

All patients receive dolastatin 10 IV bolus every 3 weeks. Patients continue treatment until disease progression, unacceptable toxicity, or patient's withdrawal from the study.

PROJECTED ACCRUAL: A maximum of 74 patients will be accrued for this study over 15 months.

Phase 2
Masking: None (Open Label)
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
Drug: dolastatin 10
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
February 2003
Not Provided


  • Histologic or cytologic diagnosis of indolent lymphoma as defined by International Working Formulation categories A-C or diagnosis of Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia
  • Lymphoma must be stage III, IV, or recurrent (no primary CNS lymphoma or lymphomatous meningitis)
  • Waldenstrom's macroglobulinemia must have at least one of the following:

    • IGM greater than 3,000 mg/dL
    • Hemoglobin less than 10.0 g/dL
    • Bone marrow involvement greater than 30% lymphocytes
    • At least 2 cm lymphadenopathy
    • Serum viscosity greater than 3.0
  • Chronic lymphocytic leukemia must be intermediate or high risk stages I-IV and have progressed on fludarabine therapy unless patient cannot tolerate fludarabine

    • Intermediate risk group must have at least one indication of active disease:

      • Presence of any one of the disease related B symptoms: 10% or more loss of body weight over the preceding 6 month period, extreme fatigue, fever above 100 degrees F without evidence of infection, or night sweats
      • Massive (greater than 6 cm below left costal margin) or progressive splenomegaly
      • Massive (greater than 10 cm in longest diameter) or progressive lymphadenopathy
      • Progressive lymphocytosis with an increase of 50% over a 2 month period or anticipated doubling time of less than 12 months
      • Evidence of progressive marrow failure as manifested by the development or worsening of anemia and/or thrombocytopenia
      • Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid therapy
  • Intolerance, relapse, or failure following prior fludarabine allowed
  • Measurable or evaluable disease
  • No untreated immediate life threatening tumor complications



  • 18 and over

Performance status:

  • CALGB 0-2

Life expectancy:

  • Not specified


  • See Disease Characteristics
  • WBC at least 4,000/mm^3*
  • Absolute granulocyte count at least 1,500/mm^3*
  • Platelet count at least 100,000/mm^3*
  • Hemoglobin at least 9 g/dL* NOTE: *Unless documented bone marrow involvement


  • Bilirubin no greater than 1.5 mg/dL
  • SGOT no greater than 2.5 times upper limit of normal


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 60 mL/min


  • No prior malignancy except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, well differentiated stage IA prostate cancer, or any other cancer from which the patient has been disease free for five years
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • No prior autologous bone marrow or stem cell transplantation


  • See Disease Characteristics
  • No more than 2 prior systemic regimens for treatment of lymphoma
  • No chemotherapy for treatment of any other prior malignancy
  • At least 4 weeks since chemotherapy and recovered
  • Prior fludarabine therapy allowed

Endocrine therapy:

  • See Disease Characteristics


  • Prior radiotherapy allowed (index lesion cannot be within prior radiotherapy field)


  • Recovered from prior surgery
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000066360 ( Registry Identifier: PDQ (Physician Data Query) )
Not Provided
Not Provided
Not Provided
Not Provided
University of Vermont
National Cancer Institute (NCI)
Study Chair: Steven M. Grunberg, MD University of Vermont
National Cancer Institute (NCI)
November 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP